Management of Fetal Growth Restriction at Term: Angiogenic Factors Versus Feto-placental Doppler

NACompletedINTERVENTIONAL
Enrollment

1,088

Participants

Timeline

Start Date

September 21, 2020

Primary Completion Date

December 18, 2022

Study Completion Date

December 18, 2022

Conditions
Fetal Growth Retardation
Interventions
PROCEDURE

Management based on sFlt-1/PlGF values

"In women allocated to the intervention group, the sFlt-1/PlGF result will be revealed to the investigators that will act according to the results of sFlt/PlGF:~* Fetuses with sFlt-1/PlGF ≥38, elective delivery will be recommended immediately (within 24h) at ≥37 weeks.~* Fetuses with sFlt-1/PlGF \<38 weekly follow up will be recommended and delivery at ≥40 weeks."

Trial Locations (20)

Unknown

Hospital Universitario de A Coruña, A Coruña

Hospital General de Alicante, Alicante

Hospital Germans Trias i Pujol, Badalona

Hospital Universitari Vall d'hebron, Barcelona

Hospital Universitario de Cabueñes, Cabueñes

Hospital Universitario Puerta del Mar, Cadiz

Hospital General Universitario de Elche, Elche

Hospital Universitario de Getafe, Getafe

Hospital Universitari Doctor Josep Trueta, Girona

Hospital Sant Joan de Deu de Manresa, Manresa

Hospital Clínico Universitario Virgen de la Arrixaca, Murcia

Hospital Son Llàtzer, Palma de Mallorca

Consorci Corporació Sanitària Parc Taulí de Sabadell, Sabadell

Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife

Hospital Universitario Virgen de Valme, Seville

Hospital Universitari Joan XXIII, Tarragona

Hospital de Terrassa, Terrassa

Hospital Universitari Mútua Terrassa, Terrassa

Hospital Universitario de Torrejon, Torrejón de Ardoz

Hospital Clinico Universitario Lozano Blesa, Zaragoza

All Listed Sponsors
lead

Hospital Universitari Vall d'Hebron Research Institute

OTHER

NCT04502823 - Management of Fetal Growth Restriction at Term: Angiogenic Factors Versus Feto-placental Doppler | Biotech Hunter | Biotech Hunter